Want to see PPCB full AI Analyst Report?
Top Page
Propanc Biopharma
(NASDAQ:PPCB)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.61
▼(-40.10% Downside)
Action:Reiterated
Date:09/26/26
The score is weighed down primarily by weak financial performance (no revenue, recurring losses, and ongoing cash burn) and bearish technicals (price below major moving averages with negative MACD). Valuation adds little support due to a loss-driven negative P/E and no dividend, while the only meaningful offset is a modestly positive board appointment.
Positive Factors
Promising preclinical efficacy
The reported animal data indicate that PRP may address several difficult features of pancreatic cancer, including metastatic burden, fibrosis, and treatment resistance. If these effects translate clinically, the candidate could offer differentiated therapeutic value beyond conventional treatment alone.
Negative Factors
No commercial revenue
With no revenue base, PPCB has not yet demonstrated commercial demand or the ability to fund operations through customers. Its financial outlook therefore remains dependent on successful clinical progress, eventual commercialization, and access to capital rather than an established operating franchise.
Read all positive and negative factors
Positive Factors
Negative Factors
Promising preclinical efficacy
The reported animal data indicate that PRP may address several difficult features of pancreatic cancer, including metastatic burden, fibrosis, and treatment resistance. If these effects translate clinically, the candidate could offer differentiated therapeutic value beyond conventional treatment alone.
Read all positive factors
Propanc Biopharma (PPCB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.11M
Dividend YieldN/A
Average Volume (3M)3.59M
Price to Earnings (P/E)―
Beta (1Y)-0.82
Revenue GrowthN/A
EPS Growth98.95%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,503,116
10 Day Avg. Volume328,045
30 Day Avg. Volume3,592,481
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.18
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Propanc Biopharma Business Overview & Revenue Model
Company Description
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeuti...
Propanc Biopharma Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
42
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -21.66K | -17.76K | -5.67K |
| EBITDA | -17.68M | -18.19M | -58.34M | -1.26M | -2.23M | -2.14M |
| Net Income | -18.36M | -18.86M | -58.92M | -1.82M | -2.66M | -2.66M |
Balance Sheet | ||||||
| Total Assets | 14.33M | 12.78M | 19.63M | 72.36K | 60.33K | 81.65K |
| Cash, Cash Equivalents and Short-Term Investments | 443.70K | 832.01K | 12.09K | 21.09K | 10.05K | 4.07K |
| Total Debt | 1.57M | 48.31K | 1.73M | 948.27K | 545.92K | 1.04M |
| Total Liabilities | 4.51M | 3.38M | 5.73M | 3.85M | 3.18M | 3.11M |
| Stockholders Equity | 9.83M | 9.40M | 13.91M | -3.78M | -3.12M | -3.02M |
Cash Flow | ||||||
| Free Cash Flow | -4.11M | -5.68M | -405.17K | -935.12K | -1.11M | -1.44M |
| Operating Cash Flow | -4.11M | -5.68M | -405.17K | -935.12K | -1.11M | -1.44M |
| Investing Cash Flow | -4.92K | -4.93K | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 4.49M | 6.46M | 490.76K | 941.89K | 1.11M | 1.49M |
Propanc Biopharma Technical Analysis
Negative
1.01
Price Trends
1.09
Negative
1.44
Negative
4.24
Negative
Market Momentum
-0.16
Positive
36.67
Neutral
14.54
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PPCB, the sentiment is Negative. The current price of 1.01 is above the 20-day moving average (MA) of 0.87, below the 50-day MA of 1.09, and below the 200-day MA of 4.24, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 36.67 is Neutral, neither overbought nor oversold. The STOCH value of 14.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PPCB.
Propanc Biopharma Risk Analysis
Propanc Biopharma disclosed 51 risk factors in its most recent earnings report. Propanc Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Propanc Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $19.61M | -0.39 | -165.71% | ― | ― | 77.68% | |
49 Neutral | $5.69M | -0.33 | -41.95% | ― | ― | 99.50% | |
42 Neutral | $2.11M | -0.02 | -148.23% | ― | ― | 98.95% | |
42 Neutral | $11.04M | -0.04 | -816.56% | ― | ― | 85.06% | |
33 Underperform | $3.99M | -0.12 | -91.95% | ― | -51.33% | 99.22% |
* Healthcare Sector Average
PPCB
Propanc Biopharma
0.63
-44.87
-98.62%
CLRB
Cellectar Biosciences
1.80
-3.72
-67.39%
MBRX
Moleculin Biotech
0.60
-11.70
-95.11%
NCNA
Nucana
1.28
-2.73
-68.08%
GNPX
Genprex
3.29
-193.39
-98.33%
ONCO
Onconetix
1.03
-168.47
-99.39%
Propanc Biopharma Corporate Events
Business Operations and StrategyExecutive/Board Changes
Propanc Biopharma Appoints New Director to Board
Positive
Jul 15, 2026
On July 8, 2026, Propanc Biopharma director Annie Van Broekhoven retired and resigned from the company’s board, marking a change in its governance structure. The board immediately filled the vacancy by appointing qualified accountant Carlo C...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.